Jordyn Sava is an editor for Targeted Oncology.
Chemotherapy Regimens Remain Key to Survival in Post EGFR-TKI NSCLC Harboring EGFR Mutations
July 10th 2023The most effective regimen has yet to be determined for patients with EGFR-mutated non–small cell lung cancer after progression on an EGFR-tyrosine kinase inhibitor. But chemotherapy regimens remain standard.
NCCN Update Aids Clinicians in Managing Methotrexate Toxicities
June 27th 2023Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.
MET Overexpression as a Predictive Biomarker in Post-Osimertinib NSCLC
June 26th 2023In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.